Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Orion Oyj (ORNBV.HE)
Espoo, FI
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.99% | -0.35% | +4.22% | +5.76% | +16.14% | +13.11% | +19.04% | +80.85% | +103.41% | +122.02% | +265.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+22.5% ★ Q1'26: +17.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+51.5% ★ Q1'26: +45.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+10.7% Q1'26: +5.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+33.4% ★ Q1'26: +27.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+35.2% ★ Q1'26: +29.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.48× Q1'26: 0.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.02B
est: 1.01B (+0.4%)
|
1.07B
est: 1.07B (+0.7%)
|
1.08B
est: 1.09B (-0.2%)
|
977.40M
est: 974.70M (+0.3%)
|
1.05B
est: 1.04B (+0.8%)
|
1.08B
est: 1.09B (-0.9%)
|
1.04B
est: 1.03B (+0.9%)
|
1.34B
est: 1.35B (-0.4%)
|
1.19B
est: 1.26B (-5.5%)
|
1.54B
est: 1.52B (+1.5%)
|
1.89B
est: 1.89B (+0.1%)
|
2.07B
2.03B – 2.10B
+9.6% YoY
|
2.31B
2.24B – 2.39B
+11.7% YoY
|
2.52B
2.51B – 2.52B
+8.9% YoY
|
2.62B
2.56B – 2.69B
+4.2% YoY
|
2.70B
2.64B – 2.77B
+3.0% YoY
|
| EBITDA |
309.30M
est: 315.95M (-2.1%)
|
355.60M
est: 333.06M (+6.8%)
|
322.50M
est: 339.65M (-5.0%)
|
293.90M
est: 304.47M (-3.5%)
|
309.60M
est: 325.69M (-4.9%)
|
334.80M
est: 339.79M (-1.5%)
|
288.70M
est: 322.38M (-10.4%)
|
489.60M
est: 420.31M (+16.5%)
|
328.20M
est: 399.23M (-17.8%)
|
513.50M
est: 482.12M (+6.5%)
|
631.70M
est: 598.45M (+5.6%)
|
656.17M
644.00M – 666.86M
+9.6% YoY
|
732.90M
711.71M – 757.32M
+11.7% YoY
|
797.85M
795.09M – 800.61M
+8.9% YoY
|
831.68M
811.70M – 852.70M
+4.2% YoY
|
856.76M
836.18M – 878.41M
+3.0% YoY
|
| EBIT |
267.50M
est: 268.72M (-0.5%)
|
315.50M
est: 283.27M (+11.4%)
|
283.90M
est: 288.87M (-1.7%)
|
253.10M
est: 258.95M (-2.3%)
|
253.10M
est: 277.00M (-8.6%)
|
279.50M
est: 288.99M (-3.3%)
|
243.60M
est: 274.19M (-11.2%)
|
441.80M
est: 357.47M (+23.6%)
|
277.10M
est: 353.36M (-21.6%)
|
420.70M
est: 426.72M (-1.4%)
|
631.70M
est: 529.68M (+19.3%)
|
580.77M
570.00M – 590.23M
+9.6% YoY
|
648.68M
629.92M – 670.29M
+11.7% YoY
|
706.17M
703.72M – 708.61M
+8.9% YoY
|
736.11M
718.43M – 754.72M
+4.2% YoY
|
758.30M
740.09M – 777.47M
+3.0% YoY
|
| Net Income |
208.20M
est: 206.78M (+0.7%)
|
249.00M
est: 236.69M (+5.2%)
|
226.00M
est: 220.99M (+2.3%)
|
330.30M
est: 194.14M (+70.1%)
|
200.40M
est: 195.95M (+2.3%)
|
219.90M
est: 235.33M (-6.6%)
|
193.80M
est: 201.21M (-3.7%)
|
349.50M
est: 356.44M (-1.9%)
|
216.80M
est: 232.30M (-6.7%)
|
329.90M
est: 322.77M (+2.2%)
|
500.30M
est: 529.40M (-5.5%)
|
543.17M
512.86M – 579.30M
+2.6% YoY
|
627.89M
577.52M – 718.38M
+15.6% YoY
|
704.90M
646.81M – 850.10M
+12.3% YoY
|
712.11M
689.87M – 735.51M
+1.0% YoY
|
771.54M
747.45M – 796.89M
+8.3% YoY
|
| SGA |
236.60M
est: 234.18M (+1.0%)
|
243.40M
est: 246.86M (-1.4%)
|
247.70M
est: 251.75M (-1.6%)
|
238.30M
est: 225.67M (+5.6%)
|
263.50M
est: 241.40M (+9.2%)
|
253.20M
est: 251.85M (+0.5%)
|
238.90M
est: 238.95M (0.0%)
|
279.10M
est: 311.53M (-10.4%)
|
299.60M
est: 282.48M (+6.1%)
|
359.80M
est: 341.13M (+5.5%)
|
376.30M
est: 423.44M (-11.1%)
|
464.28M
455.67M – 471.85M
+9.6% YoY
|
518.57M
503.57M – 535.85M
+11.7% YoY
|
564.53M
562.57M – 566.48M
+8.9% YoY
|
588.46M
574.33M – 603.34M
+4.2% YoY
|
606.21M
591.65M – 621.53M
+3.0% YoY
|
| EPS |
1.48
est: 1.47 (+0.6%)
|
1.77
est: 1.68 (+5.1%)
|
1.61
est: 1.57 (+2.4%)
|
2.35
est: 1.38 (+70.1%)
|
1.43
est: 1.39 (+2.6%)
|
1.57
est: 1.67 (-6.2%)
|
1.38
est: 1.43 (-3.6%)
|
2.49
est: 2.54 (-1.8%)
|
1.54
est: 1.65 (-6.9%)
|
2.35
est: 2.29 (+2.5%)
|
3.56
est: 3.66 (-2.8%)
|
3.86
3.65 – 4.12
+5.3% YoY
|
4.47
4.11 – 5.11
+15.7% YoY
|
5.06
4.60 – 6.04
+13.2% YoY
|
5.06
4.90 – 5.23
+0.1% YoY
|
5.49
5.31 – 5.67
+8.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liisa Hurme | President, Chief Executive Officer & Chairman of Executive Management Board | 1M | — |
| Hao Pan | Executive VP of the Branded Products & Member of the Exe. Mgmt. Board | — | male |
| Juhani Kankaanpaa | Executive VP of Global Operations & Member of Executive Management Board | — | male |
| Julia Irene Macharey | Executive VP of People & Culture & Member of Management Board | — | female |
| Mikko Kemppainen | General Counsel, Secretary to the Board & Member of Executive Management Board | — | male |
| Niclas Lindstedt EMBA | Executive VP of Animal Health & Member of the Exe. Mgmt. Board | — | male |
| Outi Vaarala | Executive VP of Research & Development and Member of the Exe. Mgmt. Board | — | — |
| Rene Lindell | Chief Financial Officer & Member of Group Executive Management Board | — | male |
| Satu Ahomäki | Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board | — | female |
| Terhi Ormio | Vice President of Communications | — | female |
| Berkeley Vincent | Executive Vice President of Innovative Medicines & Member of Management Board | — | male |
| Tuukka Hirvonen | Investor Relations & Financial Communications Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORNBV.HE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
